Penningtons Manches advises on Enterprise Therapeutics £4 million fundraising

Posted: 18/11/2016

Penningtons Manches’ corporate and life sciences teams have advised long-standing client Enterprise Therapeutics Limited on its recent £4 million funding round.

Brighton-based Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The funding was led by existing investors Epidarex Capital and Imperial Innovations and will be used to accelerate the company’s three drug discovery projects towards drug candidate selection.

Enterprise Therapeutics is developing novel muco-regulatory therapies for patients suffering with cystic fibrosis, Chronic Obstructive Pulmonary Disease and severe asthma. To achieve this, the company is targeting mechanisms that increase the clearance of mucus or reduce levels of mucus production in order to alleviate the symptoms and complications associated with respiratory disease.

The Penningtons Manches team was led by corporate partner James Went, supported by life sciences partner Jim Kinnier-Wilson and corporate associate Attilio Leccisotti. James Went commented: “It’s a pleasure to see Enterprise Therapeutics making progress on these important challenges and we look forward to working with them as they continue their development.”

Return to news headlines